IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?

The real signal here is not which fund is “better,” but which factor regime you want to own. IHE is effectively a low-volatility, cash-return vehicle on large-cap pharma, so it should keep attracting allocators if real rates stay sticky and investors continue preferring earnings quality over clinical optionality. BBH is the opposite: it is a leveraged expression of biotech beta, where valuation depends more on the capital markets window and binary clinical/regulatory outcomes than on near-term fundamentals.

Second-order, the concentration inside IHE matters more than the broad basket framing suggests. If one of the large weights disappoints on pricing, pipeline execution, or litigation, the fund can behave like a single-stock proxy; that creates hidden idiosyncratic risk despite the “defensive” label. BBH’s smaller, more concentrated roster makes it even more sensitive to financing conditions: a reopening of follow-on issuance, lower discount rates, or a stronger M&A backdrop can change the tape quickly because many constituents are duration assets with embedded optionality.

The market likely overstates the stability gap and understates the asymmetry in BBH. In a risk-on tape with falling yields, biotech usually outperforms on multiple expansion before earnings catch up; in that regime, BBH can close the performance gap fast. Conversely, if real yields remain elevated or a few high-profile trial misses hit the group, BBH’s underperformance can extend for months as investors keep paying up for dividend-backed visibility in IHE.

Bottom line: this is a portfolio-construction decision, not a strong directional alpha signal. The cleanest expression is relative value on the factor spread, not an outright sector call.